icon
0%

T Rowe Price Group TROW - News Analyzed: 6,672 - Today: 100 - Last Week: 100 - Last Month: 500

↑ T. Rowe Price Group TROW: A Flourishing Bio-Tech Investment Despite High Outflows

T. Rowe Price Group TROW: A Flourishing Bio-Tech Investment Despite High Outflows

The T. Rowe Price Group TROW has seen a 3.8% rise in its Assets Under Management (AUM), pushing its total to $1.62 trillion despite high outflows. In recent company moves, TROW has added three new active ETFs to extend their offering, showing innovative dynamism in product development. There are both purchases and sales of TROW’s shares by various investment management companies, notably the Assenagon Asset Management and Smithbridge Asset Management acquisitions. Simultaneously, sales by companies like Salem Investment and Northeast Investment do indicate some volatility. Impressively, Q1 EPS forecast for the TROW Group was elevated by analysts. Zacks Research also holds an optimistic outlook for TROW’s Q1 earnings, hinting at a strong financial performance. However, stock sold by entities like Congress Asset Management and notable stake reductions contributed to a more nuanced scenario. Despite the mixed trading, analysts have praised TROW for its strong dividend growth, making it a top choice for long-term investment. Further, Goldman Sachs increased its price target on the firm while maintaining a sell rating, suggesting some value in the invesment.

T Rowe Price Group TROW News Analytics from Wed, 20 Nov 2024 08:00:00 GMT to Sat, 14 Jun 2025 18:13:59 GMT - Rating 6 - Innovation 2 - Information 7 - Rumor -3

The email address you have entered is invalid.